Long term response and survival after thalidomide in relapsed/wrefractory multiple myeloma

被引：0
|
作者：
Zappasodi, P. [1 ]
Corso, A. [1 ]
Barbarano, L. [2 ]
Brasca, P. [2 ]
Petrucci, M. T. [3 ]
Calabrese, E. [3 ]
Palumbo, A. [4 ]
Bringhen, S. [4 ]
Pascutto, C. [1 ]
Mangiacavalli, S. [1 ]
Varettoni, M. [1 ]
Pica, G. M. [1 ]
Lazzarinu, M. [1 ]
机构：
[1] Univ Pavia, Fondaz IRCCS Policlin S Matteo, Div Ematol, I-27100 Pavia, Italy
[2] Osped Niguarda Milano, Div Ematol, Milan, Italy
[3] Univ Roma La Sapienza, Dipartimento Biotecnol Cellular Ematol, Rome, Italy
[4] Univ Turin, AO S Giovanni Battista, Div Ematol, Turin, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：137 / 137
页数：1
相关论文
共 50 条
  • [1] Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Kumar, S
    Gertz, MA
    Dispenzieri, A
    Lacy, MQ
    Geyer, SM
    Iturria, NL
    Fonseca, R
    Hayman, SR
    Lust, JA
    Kyle, RA
    Greipp, PR
    Witzig, TE
    Rajkumar, SV
    MAYO CLINIC PROCEEDINGS, 2003, 78 (01) : 34 - 39
  • [2] Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration
    Cibeira, M. Teresa
    Rosinol, Laura
    Ramiro, Laia
    Esteve, Jordi
    Torrebadell, Montserrat
    Blade, Joan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (06) : 486 - 492
  • [3] Durability of response with thalidomide therapy for relapsed multiple myeloma
    Myers, B
    Jones, SG
    Dolan, G
    7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION, 2002, : 259 - 262
  • [4] An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
    Hus, I
    Dmoszynska, A
    Manko, J
    Hus, M
    Jawniak, D
    Soroka-Wojtaszko, M
    Hellmann, A
    Ciepluch, H
    Skotnicki, A
    Wolska-Smolen, T
    Sulek, K
    Robak, T
    Konopka, L
    Kloczko, J
    BRITISH JOURNAL OF CANCER, 2004, 91 (11) : 1873 - 1879
  • [5] An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
    I Hus
    A Dmoszynska
    J Manko
    M Hus
    D Jawniak
    M Soroka-Wojtaszko
    A Hellmann
    H Ciepluch
    A Skotnicki
    T Wolska-Smolen
    K Sulek
    T Robak
    L Konopka
    J Kloczko
    British Journal of Cancer, 2004, 91 : 1873 - 1879
  • [6] Durable response to thalidomide in relapsed/refractory multiple myeloma (MM).
    Raza, SN
    Veksler, Y
    Sabir, T
    Li, ZJ
    Anderson, L
    Jagannath, S
    BLOOD, 2000, 96 (11) : 168A - 169A
  • [7] Thalidomide in the treatment of relapsed multiple myeloma
    Rajkumar, SV
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Lust, JA
    Witzig, TE
    Kyle, RA
    Gertz, MA
    Greipp, PR
    MAYO CLINIC PROCEEDINGS, 2000, 75 (09) : 897 - 901
  • [8] Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide.
    Helgason, HH
    Smit, WM
    de Groot, MR
    Schenkeveld, CEI
    Neef, C
    Schaafsma, MR
    BLOOD, 2002, 100 (11) : 387B - 387B
  • [9] Response rate and durablity of response with thalidomide therapy for relapsed multiple myeloma (MM).
    Rajkumar, SV
    Dispenzieri, A
    Lacy, M
    Geyer, S
    Iturria, N
    Fonseca, R
    Hayman, SR
    Lust, JA
    Kyle, R
    Greipp, PR
    Gertz, MA
    Witzig, TE
    BLOOD, 2001, 98 (11) : 162A - 163A
  • [10] Thalidomide in relapsed or refractory multiple myeloma: How much and for how long?
    Abdalla, SH
    Mahmoud, S
    LEUKEMIA & LYMPHOMA, 2003, 44 (06) : 989 - 991
12345